CHMA - Chiasma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Chiasma, Inc.

460 Totten Pond Road
Suite 530
Waltham, MA 02451
United States

Full Time Employees18

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark J. FitzpatrickPres & Principal Financial Officer770.3kN/A1963
Mr. Drew EnamaitVP of Admin. and Principal Accounting Officer315.1kN/A1974
Dr. William H. LudlamSr. VP of Clinical Devel. & Medical Affairs505.95kN/A1965
Mr. Raj KannanCEO & DirectorN/AN/A1964
Dr. Gary PatouHead of ClinicalN/AN/A1959
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Chiasma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.